Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.47 |
| ▸ | ARG2 | P78540 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31106404 | 1.00 | ARG1 (0.47) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL17393104 | 0.98 | ARG1 (0.46) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL1359695 | 0.94 | ARG1 (0.53) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL30085352 | 0.94 | ARG1 (0.53) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL1359692 | 0.94 | ARG1 (0.53) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL5928185 | 0.81 | NPSR1 (0.40) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL7094527 | 0.80 | ARG2 (0.60) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL17393020 | 0.79 | NPSR1 (0.39) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL29842911 | 0.79 | CYP2D6 (0.45) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL11650757 | 0.78 | ARG1 (0.58) | ARG1ARG2CYP2D6SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4374877-A2 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| EP-3928779-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-03-06 | — | — | EP | disclosed |
| EP-3928779-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | Chugai Seiyaku Kabushiki Kaisha (JP) | 2021-12-29 | — | — | EP | disclosed |
| EP-3192511-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-07-14 | — | — | EP | disclosed |
| EP-3757093-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-12-30 | — | — | EP | disclosed |
| EP-2975030-B1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-07-15 | — | — | EP | disclosed |
| US-10159745-B2 | Tubulysin derivatives | MEDIMMUNE, LLC (US) | 2018-12-25 | — | — | US | disclosed |
| CN-105073715-B | The derovatives of dihydrogen dazin 3,5 | 中外制药株式会社 | 2017-12-01 | — | — | CN | disclosed |
| CN-107072993-A | Medicine containing sodium dependence phosphate transporter inhibitor | 中外制药株式会社 | 2017-08-18 | — | — | CN | disclosed |
| EP-3192511-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | Chugai Seiyaku Kabushiki Kaisha (JP) | 2017-07-19 | — | — | EP | disclosed |
| EP-0798119-A2 | Ink jet recording method and recording apparatus using same | CANON KABUSHIKI KAISHA (JP) | 1997-10-01 | — | — | EP | disclosed |
| US-5518735-A | ANTICOAGULANTS ADMINISTERED BY MOUTH | PENTAPHARM AG (CH) | 1996-05-21 | — | — | US | disclosed |
| EP-0296416-B1 | BENZO-ANELLATED CYCLIC COMPOUNDS | NIHON BAYER AGROCHEM K.K. (JP) | 1992-07-29 | — | — | EP | disclosed |
| EP-0230874-B1 | BENZOTHIAZOLYLAZOLIDINES, AND THEIR PRODUCTION AND USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-11-27 | — | — | EP | disclosed |
| US-4898948-A | HERBICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-02-06 | — | — | US | disclosed |
| EP-0337151-A2 | N-substituted phenyl-heterocyclic compounds | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1989-10-18 | — | — | EP | disclosed |
| US-4828605-A | HERBICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1989-05-09 | — | — | US | disclosed |
| EP-0296416-A1 | Benzo-anellated cyclic compounds | NIHON BAYER AGROCHEM K.K. (JP) | 1988-12-28 | — | — | EP | disclosed |
| US-4786310-A | HERBICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1988-11-22 | — | — | US | disclosed |
| EP-0230874-A1 | Benzothiazolylazolidines, and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10159745-B2 | Tubulysin derivatives | TEKT1, TWF2, TEK | ARG1 2067/4885ARG2 1843/4885CYP2D6 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.